RESUMO
The study examined the impact of size on lymphatic particle distribution through intrapleural (ipl.) administration. Aminopolystyrene of three sizes, 0.29 microm, 2.18 microm, and 11.2 microm were radiolabeled with 111Indium and their biodistributions were evaluated in rats after ipl administration. Animals received either particles of three different sizes (4 mg, 200 microCi/animal) or unconjugated 111Indium as control. The percentage of injected dose (%ID) per organ or sample was determined for left (L) and right (R) mediastinal lymph nodes (LN), blood, lung, and pleural wash. The biodistribution of 2.18 microm 111In-aminopolystyrene was further investigated at 6 h, 24 h, 48 h, and 72 h following ipl administration to examine the possible particle retention time. The 2.18 microm particles had significantly higher uptake in both LLN and RLN compared to other sizes. The systemic uptake was minimal. At 72 h, there was still 3.2 +/- 3.2% and 2.1 +/- 1.8% of injected dose retained in the LLN and RLN, respectively. Scintigraphic imaging revealed significant accumulation of the radioactivity in mediastinal nodes. Particle size has significant impact on lymphatic particle distribution through ipl administration. Approximately 2 microm seems to be a suitable size.
Assuntos
Radioisótopos de Índio , Linfonodos/metabolismo , Poliestirenos/farmacocinética , Animais , Sistemas de Liberação de Medicamentos , Masculino , Tamanho da Partícula , Pleura , Ratos , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
AIM: Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of this hypothermia are unknown and were studied herein. METHODS: Two hypothermia-inducing TRPV1 antagonists, the newly synthesized A-1165901 and the known AMG7905, were used in physiological experiments in rats and mice. Their pharmacological profiles against rat TRPV1 were studied in vitro. RESULTS: Administered peripherally, A-1165901 caused hypothermia in rats by either triggering tail-skin vasodilation (at thermoneutrality) or inhibiting thermogenesis (in the cold). A-1165901-induced hypothermia did not occur in rats with desensitized (by an intraperitoneal dose of the TRPV1 agonist resiniferatoxin) sensory abdominal nerves. The hypothermic responses to A-1165901 and AMG7905 (administered intragastrically or intraperitoneally) were absent in Trpv1-/- mice, even though both compounds evoked pronounced hypothermia in Trpv1+/+ mice. In vitro, both A-1165901 and AMG7905 potently potentiated TRPV1 activation by protons, while potently blocking channel activation by capsaicin. CONCLUSION: TRPV1 antagonists cause hypothermia by an on-target action: on TRPV1 channels on abdominal sensory nerves. These channels are tonically activated by protons and drive the reflectory inhibition of thermogenesis and tail-skin vasoconstriction. Those TRPV1 antagonists that cause hypothermia further inhibit these cold defences, thus decreasing body temperature. SIGNIFICANCE: TRPV1 antagonists (of capsaicin activation) are highly unusual in that they can cause both hyper- and hypothermia by modulating the same mechanism. For drug development, this means that both side effects can be dealt with simultaneously, by minimizing these compounds' interference with TRPV1 activation by protons.
Assuntos
Analgésicos/farmacologia , Hipotermia/induzido quimicamente , Canais de Cátion TRPV/antagonistas & inibidores , Analgésicos/síntese química , Animais , Capsaicina , Desenvolvimento de Medicamentos , Hipotermia/metabolismo , Masculino , Camundongos , Prótons , Ratos Sprague-Dawley , Ratos Wistar , Canais de Cátion TRPV/metabolismo , Termogênese/efeitos dos fármacos , Vasodilatação/efeitos dos fármacosRESUMO
Radiolabeled first-generation anti-tumor-associated glycoprotein-72 (TAG-72) monoclonal antibody (MAb), B72.3, has proven useful in detecting primary and secondary colorectal carcinoma. It has been anticipated that the development of second-generation, higher affinity, anti-TAG-72 MAbs, CC49 and CC83, would be of greater use in cancer detection and of value in radioimmunotherapy of human cancer. We compared the pharmacokinetics, biodistribution, and immune responses of 131I-labeled CC49 and CC83 to 125I-labeled B72.3 by preoperatively coninjecting dual-labeled MAbs into 16 colorectal cancer patients. The imaging properties of radiolabeled CC49 and CC83 were also assessed. Pharmacokinetics of all three MAbs were identical, and there were no differences in the uptake of any of three MAbs in tumor and normal tissues. Maximum tumor uptake was 0.0041% of the injected dose/g for 125I-B72.3, 0.0024% for 131I-CC49, and 0.0029% for 131I-CC83. Radiolabeled CC49 and CC83 detected most known tumor sites on scintigrams without any clear advantage for either MAb. Nonspecific splenic and testicular uptake was frequently observed. Anti-idiotypic human anti-mouse antibody responses were seen more frequently with B72.3 than with CC49 or CC83. We conclude that higher affinity, radiolabeled anti-TAG-72 MAbs can detect colorectal cancer but do not penetrate these tumors more effectively than B72.3. Improvements in tumor detection and radioimmunotherapeutic strategies will likely require the administration of smaller fragments of MAb molecules or novel delivery systems rather than the continued development of higher affinity MAbs.
Assuntos
Anticorpos Monoclonais , Antígenos de Neoplasias/metabolismo , Neoplasias Colorretais/diagnóstico , Glicoproteínas/metabolismo , Adulto , Idoso , Anticorpos Anti-Idiotípicos/imunologia , Anticorpos Antineoplásicos/metabolismo , Neoplasias Colorretais/diagnóstico por imagem , Neoplasias Colorretais/metabolismo , Feminino , Humanos , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Cintilografia , Distribuição TecidualRESUMO
UNLABELLED: The overexpression of cell surface receptors on cancer cells is a potential target for the design of receptor-binding radiopharmaceuticals for tumor imaging. The sensitivity of these agents depends on the interaction in vivo of factors such as the level and heterogeneity of receptor expression, the proportion of targeted cells, the tumor/ nontarget (T/NT) ratio and attenuation by overlying normal tissue. The relative importance of a single factor or combination of factors is unknown. Our objective was to evaluate, under controlled experimental conditions, the effect of these factors on the sensitivity for imaging breast cancer with a new receptor-binding radiopharmaceutical: human epidermal growth factor (HEGF)51 labeled with 111In. METHODS: MDA-MB-468, S1 or MCF-7 breast cancer cells expressing 1.3 x 10(6), 3.3 x 10(4) and 1.5 x 10(4) epidermal growth factor receptors (EGFR)/cell were targeted in vitro with 111In-HEGF51. Phantoms were constructed with an internal well to simulate a lesion and surrounded by an outer well to simulate normal tissue. The effect of the level of receptor expression was studied with phantoms containing targeted MDA-MB-468, S1 or MCF-7 cells. The effect of the proportion of cells targeted was evaluated using phantoms containing mixed targeted or nontargeted MDA-MB-468 cells. Receptor heterogeneity was studied using phantoms containing mixed MDA-MB-468 and S1 cells. The T/NT ratio was evaluated by varying the concentration of radioactivity in the outer well and tissue attenuation was simulated by overlaying the phantoms with water. Phantoms were imaged using a gamma camera fitted with a medium-energy collimator interfaced to a computer. RESULTS: The sensitivity for detection of a lesion was directly proportional to the level of receptor expression or to the proportion of cells targeted and inversely proportional to the level of receptor heterogeneity. A T/NT ratio > or = 2:1 was required for detection. Under ideal conditions with a single factor varied, as few as 5 x 10(4) to 10(5) MDA-MB-468 cells with a high level of EGFR expression or 2.5 x 10(5) to 10(6) S1 or MCF-7 cells with a low level of EGFR expression were detected. When the receptor heterogeneity, the proportion of targeted cells and tissue attenuation were varied in combination with a T/NT ratio of 3:1, the sensitivity for detection approached that observed clinically with receptor-binding radiopharmaceuticals (10(7) cells). CONCLUSION: Our results suggest that combinations of four factors may account for the relatively low sensitivity for tumor imaging observed clinically with receptor-binding radiopharmaceuticals and, in particular, strategies aimed at minimizing the effects of receptor heterogeneity; a low proportion of cells targeted and tissue attenuation would improve the detection of small lesions.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , Fator de Crescimento Epidérmico , Receptores ErbB/metabolismo , Neoplasias da Mama/metabolismo , Feminino , Humanos , Radioisótopos de Índio , Imagens de Fantasmas , Cintilografia , Proteínas Recombinantes , Sensibilidade e Especificidade , Células Tumorais Cultivadas/metabolismoRESUMO
UNLABELLED: Our objective was to compare 111In-labeled human epidermal growth factor (hEGF), a 53-amino acid peptide with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) 528 (IgG2a) for imaging EGFR-positive breast cancer. METHODS: hEGF and MAb 528 were derivatized with diethylenetriamine pentaacetic acid (DTPA) and labeled with 111In acetate. Receptor binding assays were conducted in vitro against MDA-MB-468 human breast cancer cells. Biodistribution and tumor imaging studies were conducted after intravenous injection of the radiopharmaceuticals in athymic mice bearing subcutaneous MCF-7, MDA-MB-231, or MDA-MB-468 human breast cancer xenografts or in severe combined immunodeficiency mice implanted with a breast cancer metastasis (JW-97 cells). MCF-7, MDA-MB-231, JW-97, and MDA-MB-468 cells expressed 1.5 x 10(4), 1.3 x 10(5), 2.7 x 10(5), and 1.3 x 106 EGFR/cell, respectively in vitro. RESULTS: 111In-DTPA-hEGF and 111In-DTPA-MAb 528 bound with high affinity to MDA-MB-468 cells (Ka of 7.5 x 10(8) and 1.2 x 10(8) L/mol, respectively). 111In-DTPA-hEGF was eliminated rapidly from the blood with < 0.2% injected dose/g (%ID/g) circulating at 72 h after injection, whereas 111In-DTPA-MAb 528 was cleared more slowly (3%ID/g in the blood at 72 h). Maximum localization of 111In-DTPA-hEGF in MDA-MB-468 tumors (2.2 %ID/g) was 10-fold lower than with 111In-DTPA-MAb 528 (21.6 %ID/g). There was high uptake in the liver and kidneys for both radiopharmaceuticals. Tumor-to-blood ratios were greater for 111In-labeled hEGF than for MAb 528 (12:1 versus 6:1), but all other tumor-to-normal tissue ratios were higher for MAb 528. MDA-MB-468 and JW-97 tumors were imaged successfully with both radiopharmaceuticals, but tumors were more easily visualized using 111In-labeled MAb 528. There was no direct quantitative relationship between EGFR expression on breast cancer cell lines in vitro, and tumor uptake of the radiopharmaceuticals in vivo, but control studies showed that tumor uptake was receptor mediated. CONCLUSION: Our results suggest that the tumor uptake in vivo of receptor-binding radiopharmaceuticals is controlled to a greater extent by their elimination rate from the blood than by the level of receptor expression on the cancer cells. Radiolabeled anti-EGFR MAbs would be more effective for tumor imaging in cancer patients than peptide-based radiopharmaceuticals such as hEGF, because they exhibit higher tumor uptake at only moderately lower tumor-to-blood ratios.
Assuntos
Anticorpos Monoclonais , Neoplasias da Mama/diagnóstico por imagem , Fator de Crescimento Epidérmico , Receptores ErbB/imunologia , Radioisótopos de Índio , Ácido Pentético , Compostos Radiofarmacêuticos , Animais , Neoplasias da Mama/química , Receptores ErbB/análise , Feminino , Humanos , Camundongos , Camundongos Nus , Transplante de Neoplasias , Cintilografia , Células Tumorais CultivadasRESUMO
UNLABELLED: Our objective was to determine whether the internalization and nuclear translocation of human epidermal growth factor (hEGF) after binding to its cell surface receptor (EGFR) could be exploited to deliver the Auger electron emitter 111In into EGFR-positive breast cancer cells for targeted radiotherapy. METHODS: hEGF was derivatized with diethylenetriamine pentaacetic acid (DTPA) and radiolabeled with 111In-acetate. The internalization of 111In-DTPA-hEGF by MDA-MB-468 breast cancer cells (1.3x10(6) EGFRs/cell) was determined by displacement of surface-bound radioactivity by an acid wash. The radioactivity in the cell nucleus and chromatin, isolated by differential centrifugation, was measured. The effect on the growth rate of MDA-MB-468 or MCF-7 (1.5x10(4) EGFRs/cell) cells was determined after treatment in vitro with 111In-DTPA-hEGF, unlabeled DTPA-hEGF, or 111In-DTPA. The surviving fraction of MDA-MB-468 or MCF-7 cells treated in vitro with 111In-DTPA-hEGF was determined in a clonogenic assay. The radiotoxicity in vivo against normal hepatocytes or renal tubular cells was evaluated by measuring alanine aminotransferase (ALT) or creatinine levels in mice administered high amounts of 111In-DTPA-hEGF (equivalent to human doses up to 14,208 MBq) and by light and electron microscopy of the tissues. RESULTS: Approximately 70% of 111In-DTPA-hEGF was internalized by MDA-MB-468 cells within 15 min at 37 degrees C and up to 15% was translocated to the nucleus within 24 h. Chromatin contained 10% of internalized radioactivity. The growth rate of MDA-MB-468 cells was decreased 3-fold by treatment with 111In-DTPA-hEGF (45-60 mBq/cell). Treatment with unlabeled DTPA-hEGF caused a 1.5-fold decrease in growth rate, whereas treatment with 111In-DTPA had no effect. Targeting of MDA-MB-468 cells with up to 130 mBq/cell of 111In-DTPA-hEGF resulted in a 2-logarithm decrease in their surviving fraction. No decrease in the growth rate or surviving fraction of MCF-7 cells was evident. There was no evidence of hepatotoxicity or renal toxicity in mice administered high amounts of 111In-DTPA-hEGF. Radiation dosimetry estimates suggest that the radiation dose to an MDA-MB-468 cell targeted with 111In-DTPA-hEGF could be as high as 25 Gy with up to 19 Gy delivered to the cell nucleus. CONCLUSION: 111In-DTPA-hEGF is a promising novel radiopharmaceutical for targeted Auger electron radiotherapy of advanced, hormone-resistant breast cancer.
Assuntos
Neoplasias da Mama/patologia , Fator de Crescimento Epidérmico/farmacologia , Receptores ErbB/metabolismo , Radioisótopos de Índio/farmacologia , Animais , Neoplasias da Mama/radioterapia , Feminino , Humanos , Técnicas In Vitro , Rim/patologia , Fígado/patologia , Camundongos , Camundongos Endogâmicos BALB C , Microscopia de Fluorescência , Doses de Radiação , Radioterapia , Células Tumorais CultivadasRESUMO
Antibodies have been investigated as specific targeting agents for cancer diagnosis and therapy, to inactivate toxic substances including drugs and also as passive immunotherapy for neoplastic or infectious diseases. In most cases the antibodies were administered systemically by the intravenous route. More recently, however, there has been increasing interest in the oral administration of antibodies for localised treatment of infections or other conditions in the gastrointestinal tract. The normal physiological handling of ingested proteins is degradation by proteases in the stomach and intestine into small peptides or amino acids which are subsequently absorbed. Proteolytic enzymes involved in the degradation of orally administered immunoglobulins include pepsin, trypsin, chymotrypsin, carboxypeptidase and elastase. These enzymes initially degrade the antibodies to F(ab')2. Fab and Fc fragments. The F(ab')2 and Fab fragments, however, retain some of their neutralising activity locally in the gastrointestinal tract. Various approaches are possible to increase the stability of orally administered antibodies against proteolysis, including formulation in liposomes, coating with polymers and genetic engineering of resistant forms. The clinical application of orally administered antibodies includes the treatment and prevention of gastrointestinal infections caused by enteric pathogens such as rotavirus, Escherichia coli or Vibrio cholerae in susceptible individuals including those with immunodeficiency diseases and patients with bone marrow transplants. There is also a suggestion that such agents may be useful in preventing chemotherapy-induced gastrointestinal mucositis. Future opportunities for research include the design of oral dosage forms of antibodies which resist proteolysis and can deliver a greater fraction of immunoreactive antibody locally in the gastrointestinal tract for the treatment of infections or perhaps even to allow the absorption of antibodies for the treatment or prevention of systemic conditions.
Assuntos
Anticorpos/administração & dosagem , Imunoglobulinas/farmacologia , Peptídeos/farmacocinética , Administração Oral , Anticorpos/metabolismo , Sistema Digestório/efeitos dos fármacos , Sistema Digestório/metabolismo , Gastroenteropatias/terapia , Engenharia Genética , Humanos , Imunização Passiva , Imunoglobulinas/administração & dosagem , Imunoglobulinas/metabolismo , Técnicas In Vitro , Infecções/terapia , Mucosa Intestinal/patologia , Mucosa Intestinal/fisiologia , Peptídeo Hidrolases/química , Peptídeo Hidrolases/metabolismo , Peptídeos/administração & dosagem , Peptídeos/metabolismoRESUMO
Monoclonal antibodies to tumour-associated antigens have great theoretical potential for the specific targeting of radioactivity and anti-neoplastic agents to tumours. The clinical success of monoclonal antibody-based cancer diagnosis and therapy depends, however, on solving a number of pharmacokinetic delivery problems. These include: (i) slow elimination of monoclonal antibodies from the blood and poor vascular permeability; (ii) low and heterogeneous tumour uptake; (iii) cross-reactivity with normal tissues; (iv) metabolism of monoclonal antibody conjugates; and (v) immunogenicity of murine forms in humans. As a result of extensive pharmaceutical and pharmacokinetic research conducted over the past 10 to 15 years, several potential solutions to these delivery problems have been identified. Blood concentrations of antibody conjugates may be reduced through regional administration, the use of antibody fragments, interventional strategies and various pre-targeting techniques. Tumour uptake may be increased through administration of higher doses, or the use of agents to increase tumour vascular permeability. Tumour retention of antibody conjugates may be improved by inhibition of metabolism, by using more stable linkage chemistry. Alternatively, normal tissue retention may be decreased through the use of metabolisable chemical linkages inserted between the antibody and conjugated moiety. Very small antigen-binding fragments and peptides that exhibit improved tumour penetration and more rapid elimination from the blood and normal tissues have been prepared by genetic engineering techniques. Chimeric (mouse/human) and human monoclonal antibodies have been developed to circumvent the problem of immunogenicity. Future research will continue to be focused on improvements in the design of monoclonal antibodies for tumour targeting, with the ultimate goal of finally uncovering the 'magic bullet' envisioned by Paul Ehrlich almost a century ago.
Assuntos
Anticorpos Monoclonais/administração & dosagem , Sistemas de Liberação de Medicamentos , Animais , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/farmacocinética , Complexo Antígeno-Anticorpo , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/imunologia , Permeabilidade Capilar/fisiologia , Reações Cruzadas , Humanos , Imunoconjugados/administração & dosagem , Imunoconjugados/metabolismo , Imunoconjugados/uso terapêutico , Fragmentos de Imunoglobulinas/metabolismo , Camundongos , Neoplasias/diagnóstico , Neoplasias/metabolismoRESUMO
Pretargeted tumour imaging was performed in nude mice bearing subcutaneous LS174T human colon cancer xenografts with streptavidin-CC49 monoclonal antibody and 111In-DTPA-biocytin. Mice were administered 250 micrograms of streptavidin-CC49, followed 6 or 9 days later by 40 ng (250 microCi) of 111In-DTPA-biocytin. Tumors were visualized at 24 h postinjection of 111In-DTPA-biocytin. Tumour uptake was 0.9-2.5% injected dose/g with tumour/nontarget ratios from 2:1 to 37:1 (except for kidney, which was 0.5-3:1). Tumour uptake in mice pretargeted with streptavidin or streptavidin-conjugated nonspecific normal mouse IgG was < 0.1% i.d./g.
Assuntos
Anticorpos Monoclonais , Proteínas de Bactérias , Neoplasias do Colo/diagnóstico por imagem , Imunoconjugados , Radioisótopos de Índio , Lisina/análogos & derivados , Ácido Pentético/análogos & derivados , Animais , Anticorpos Monoclonais/farmacocinética , Antígenos de Neoplasias/imunologia , Antígenos de Neoplasias/metabolismo , Proteínas de Bactérias/farmacocinética , Neoplasias do Colo/metabolismo , Feminino , Glicoproteínas/imunologia , Glicoproteínas/metabolismo , Humanos , Imunoconjugados/farmacocinética , Radioisótopos de Índio/farmacocinética , Lisina/farmacocinética , Camundongos , Camundongos Nus , Transplante de Neoplasias , Ácido Pentético/farmacocinética , Cintilografia , Estreptavidina , Distribuição Tecidual , Transplante HeterólogoRESUMO
Streptavidin was conjugated to the second-generation TAG-72 monoclonal antibody CC49 at lysine amino acids, oxidized carbohydrates or reduced disulfides on the immunoglobulin. The streptavidin immunoconjugates were radiolabelled with 111In-DTPA-biocytin and their immunological characteristics evaluated in vitro and in vivo. FPLC analysis showed a single peak (mol. wt > 350 kDa) for the lysine conjugate and sulfhydryl conjugate (mol. wt approximately 210 kDa) but multiple peaks (approximately 210 to > 350 kDa) for the carbohydrate conjugate. There were only small differences in immunoreactivity against bovine submaxillary mucin in vitro. However, in mice bearing subcutaneous LS174T tumours, the lysine conjugate exhibited significantly lower tumour uptake (< 2% i.d./g) compared to the other streptavidin-CC49 conjugates (10-40% i.d./g) or DTPA-CC49 (14-18% i.d./g). Due to the monomeric nature and smaller molecular size of the sulphhydryl conjugate, and its similar in vitro and in vivo characteristics compared with DTPA-CC49, this conjugate has been selected for future pretargeting studies with 111In and 90Y biotin.
Assuntos
Anticorpos Monoclonais/farmacocinética , Antígenos de Neoplasias/imunologia , Proteínas de Bactérias/farmacocinética , Glicoproteínas/imunologia , Imunoconjugados/farmacocinética , Animais , Proteínas de Bactérias/química , Humanos , Imunoconjugados/química , Rim/metabolismo , Camundongos , Camundongos Nus , Peso Molecular , Estreptavidina , Distribuição TecidualRESUMO
A method is described to amplify the delivery of 111In to human breast cancer cells utilizing a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted preferentially in the HSA domain with multiple DTPA metal chelators for 111In. 111In-DTPA-HSA-hEGF exhibited a lower receptor-binding affinity than 111In-DTPA-hEGF but was rapidly and specifically bound, internalized and translocated to the nucleus in EGFR-positive MDA-MB-468 breast cancer cells. 111In-DTPA-HSA-hEGF was cytotoxic in vitro mainly through the emission of short-range Auger electrons and partially through the effects of the hEGF moiety to MDA-MB-468 cells overexpressing EGFR (1-2 x 10(6) receptors/cell) but not towards MCF-7 breast cancer cells with a 100-fold lower level of EGFR on their surface. The cytotoxicity in vitro against MDA-MB-468 cells of 111In-DTPA-HSA-hEGF substituted with nine DTPA chelators was enhanced 4-fold compared to 111In-DTPA-hEGF monosubstituted with DTPA. Studies are planned to further evaluate 111In-DTPA-HSA-hEGF in vivo as a new imaging and targeted radiotherapeutic agent for breast cancer.
Assuntos
Neoplasias da Mama/radioterapia , Receptores ErbB/metabolismo , Radioisótopos de Índio/uso terapêutico , Albumina Sérica/metabolismo , Neoplasias da Mama/diagnóstico por imagem , Humanos , Radioisótopos de Índio/administração & dosagem , Ensaio Radioligante , CintilografiaRESUMO
Sixteen patients with colorectal cancer were administered 37-74 MBq (1 mg) of radioiodinated B72.3 monoclonal antibody. Pharmacokinetic analysis was carried out on plasma and urine samples. Elimination from the plasma was biexponential with a mean T1/2 alpha of 3.7 h and T1/2 beta of 62.4 h. The plasma clearance was fit to a two-compartmental model. This was combined with a previously reported model for radioiodine to construct a composite model. There was a good correlation (r = 0.952) between the model-predicted and observed excretion of radioiodine suggesting that the composite model is compatible with the pharmacokinetics of the radiolabelled antibody.
Assuntos
Anticorpos Monoclonais/metabolismo , Neoplasias do Colo/metabolismo , Radioisótopos do Iodo/farmacocinética , Adulto , Idoso , Animais , Neoplasias do Colo/sangue , Neoplasias do Colo/urina , Humanos , Camundongos , Pessoa de Meia-Idade , Modelos Químicos , Doses de RadiaçãoRESUMO
BACKGROUND: Chkl is a checkpoint gene that is activated after DNA damage. It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage. METHODS: We treated 184B5 cell line and its E6 transformed cell lines with adriamycin in the presence of staurosporine or UCNO1 and examined G2 arrest and cell death. RESULTS: We found that adriamycin induced a p53 and p21 response as well as a G1 arrest in 184B5 cells, but not in its E6 transformed cells. Staurosporine or UCNO1 abrogated the G2 arrest induced by adriamycin in both cell lines. In addition, staurosporine or UCNO1 specifically sensitized p53 incompetent cells to adriamycin. CONCLUSION: G2/M checkpoint abrogators can potentially enhance the cytotoxic effect of conventional chemotherapeutic reagents specifically to tumor cells.
Assuntos
Antineoplásicos/farmacologia , Dano ao DNA/efeitos dos fármacos , Doxorrubicina/farmacologia , Neoplasias/patologia , Proteína Supressora de Tumor p53/metabolismo , Alcaloides/farmacologia , Apoptose/efeitos dos fármacos , Linhagem Celular Transformada , Quinase 1 do Ponto de Checagem , Inibidores Enzimáticos/farmacologia , Fase G2 , Humanos , Neoplasias/metabolismo , Proteínas Quinases/metabolismo , Estaurosporina/farmacologia , Células Tumorais CultivadasRESUMO
99Tcm is the optimum radionuclide for imaging in nuclear medicine due to its superior physical properties (E gamma of 140 keV and t1/2 of 6 h). Several techniques have recently been developed for labelling monoclonal antibodies with 99Tcm for immunoscintigraphy of human malignancies. These techniques primarily consist of either direct labelling of endogenous sulphydryl groups on the immunoglobulin with 99Tcm or indirect labelling through conjugation of a preformed 99Tcm-chelate. Direct methods offer the best promise for a one-step labelling kit but the 99Tcm-antibody may be unstable in vivo. This instability has been advantageous, however, in reducing blood background radioactivity and achieving sufficiently high tumour/blood ratios for clinical imaging. Over 1200 patients have been studied with 99Tcm-labelled monoclonal antibodies in the past decade. The majority of studies have been carried out in melanoma or colon cancer but other malignancies have also been investigated. The sensitivity has been variable and depended both on the size of the lesion and its location. Single photon emission computed tomographic imaging was helpful in some instances. Further study of labelling techniques and their effect on the pharmacokinetics of 99Tcm-labelled monoclonal antibodies as well as additional clinical evaluation of these agents is indicated.
Assuntos
Neoplasias/diagnóstico por imagem , Radioimunodetecção , Tecnécio , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Radioimmunotherapy of solid malignancies using directly labelled 90Y-monoclonal antibodies has been associated in clinical trials with dose-limiting bone marrow toxicity. Our objective in this study was to evaluate the efficacy and toxicity of an alternative two-step pre-targeted radioimmunotherapy protocol for the treatment of human colon cancer. The two-step protocol consisted of administration of the tumour-associated glycoprotein (TAG-72) monoclonal antibody CC49 conjugated to streptavidin, followed by administration of 90Y-DOTA-biotin. Swiss nu/nu athymic mice bearing subcutaneous LS174T human colon cancer xenografts were injected intraperitoneally with streptavidin-CC49 (250 micrograms), followed 40 h later by an intravenous injection of 90Y-DOTA-biotin (900 microCi, 40 micrograms). Tumour growth was measured over 25 days and compared with that in control mice receiving no treatment. Bone marrow and normal tissue toxicity was determined by peripheral blood leucocyte counts and by monitoring the body weight of the animals. Pre-targeted radioimmunotherapy resulted in a modest (30-40%) decrease in the mean tumour growth rate in treated mice compared to control animals. There was no change in body weight following treatment and peripheral blood leucocyte counts remained within the normal range. Pre-targeted radioimmunotherapy was safe at administered amounts of 90Y radioactivity, which were at least nine-fold higher than those previously determined to be lethal using directly labelled 90Y-monoclonal antibodies. The results of this study are promising for the application of pre-targeted radioimmunotherapy using streptavidin-CC49 and 90Y-DOTA-biotin for the treatment of advanced colorectal cancer in humans.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Anticorpos Antineoplásicos/uso terapêutico , Biotina/análogos & derivados , Neoplasias do Colo/terapia , Compostos Organometálicos/uso terapêutico , Radioimunoterapia/métodos , Animais , Antígenos de Neoplasias/imunologia , Biomarcadores Tumorais , Biotina/uso terapêutico , Neoplasias do Colo/patologia , Glicoproteínas/imunologia , Humanos , Indicadores e Reagentes , Camundongos , Camundongos Nus , Transplante de Neoplasias , Estreptavidina , Transplante Heterólogo , Radioisótopos de ÍtrioRESUMO
Determining the radiochemical purity of 99Tcm-HMPAO using the standard method suggested by the manufacturer of the HMPAO kit is slow, consuming much of the 30 min useful shelf-life of the radiopharmaceutical. We have compared two new methods (a solvent extraction technique and a method involving a disposable, pre-packed reverse phase chromatography cartridge) with the standard method for determining the radiochemical purity of 99Tcm-HMPAO. There were no significant differences (F test, p less than 0.05) in the results obtained by all three methods. However, the reversed phase chromatography method gave better agreement (correlation coefficient of 0.877) with results obtained using the standard method than did the solvent extraction technique (correlation coefficient of 0.693). The solvent extraction technique took about 10 min to perform whereas the reversed phase chromatography method took only 5 min. Both of the new methods did not achieve complete separation of the secondary, less lipophilic 99Tcm-HMPAO complex from the primary, lipophilic 99Tcm-HMPAO complex but the error introduced was small (typically only 3-5%). The new methods offer the capability of determining the radiochemical purity of 99Tcm-HMPAO quickly, reliably and accurately, prior to administration of the radiopharmaceutical to the patient.
Assuntos
Compostos de Organotecnécio/normas , Oximas/normas , Compostos de Organotecnécio/análise , Oximas/análise , Radioquímica , Kit de Reagentes para Diagnóstico , Tecnécio Tc 99m ExametazimaRESUMO
The thin layer chromatographic (TLC) method for determining the radiochemical purity of 99Tcm-sestamibi suggested by the manufacturer of the kit is slow and inconvenient. In this study a more rapid reversed phase chromatography (Sep-Pak) technique is compared with the TLC method for measurement of the radiochemical purity of 99Tcm-sestamibi. The levels of free 99Tcm-pertechnetate in 99Tcm-sestamibi were accurately determined using the Sep-Pak technique. However, due to binding of variable amounts of reduced-hydrolysed unbound 99Tcm to the chromatography cartridge, the Sep-Pak method overestimated the radiochemical purity of the radiopharmaceutical by approximately 3%. In practice, this overestimation is not important and the Sep-Pak technique can be used as a rapid method of determining radiochemical purity of 99Tcm-sestamibi.
Assuntos
Tecnécio Tc 99m Sestamibi/normas , Controle de Qualidade , Fatores de TempoRESUMO
Monoclonal antibody CC83 is a second-generation high-affinity antibody directed against the TAG-72 antigen in colorectal cancer. Our objectives were to evaluate the biodistribution, pharmacokinetics and imaging properties of CC83 labelled with 99Tcm via a modified Schwartz technique. The immunological integrity of 99Tcm-CC83 was evaluated by size-exclusion FPLC and by determining the immunoreactive fraction in vitro against bovine submaxillary mucin. The biodistribution of 99Tcm-CC83 up to 24 h postinjection was evaluated in nude mice bearing subcutaneous LS174T human colon cancer xenografts. Blood radioactivity data was fitted to a one-compartment pharmacokinetic model. Images of tumour-bearing mice were obtained at 17-24 h postinjection with 99Tcm-CC83. 99Tcm-CC83 was eluted as intact immunoglobulin by FPLC analysis and the mean immunoreactive fraction was 0.49 +/- 0.15. Tumour uptake at 24 h postinjection was 11.2 +/- 4.1% i.d.g-1. Radioactivity in the blood was eliminated rapidly with a half-life of 8 h and tumour:blood ratios were > 2:1 at 24 h postinjection. LS174T tumours were successfully imaged in 3/3 mice. In vitro studies showed instability of 99Tcm-CC83 when challenged with cysteine and glutathione but not metallothionein, suggesting a metabolic route for the 99Tcm antibody in vivo. We conclude that CC83 labelled directly with 99Tcm retains its immunological integrity and capability specifically to target subcutaneous LS174T human colon cancer tumours hosted in nude mice. These results further suggest that 99Tcm-CC83 may have potential for imaging colorectal cancer in humans.
Assuntos
Neoplasias do Colo/diagnóstico por imagem , Radioimunodetecção/métodos , Animais , Humanos , Melanoma Experimental/diagnóstico por imagem , Camundongos , Camundongos Nus , Transplante de Neoplasias , Distribuição Tecidual , Transplante HeterólogoRESUMO
H11 is a human IgM monoclonal antibody which recognizes a novel tumour-associated antigen expressed on melanoma, glioma, breast cancer, colon cancer, prostate cancer, lung cancer and B-cell lymphoma. In this study, a recombinant single-chain Fv (scFv) fragment of H11 labelled with 111In was investigated for tumour imaging in athymic mice implanted subcutaneously with A-375 human melanoma xenografts. H11 scFv was derivatized with diethylenetriaminepentaacetic acid (DTPA) for labelling with 111In. The immunoreactivity of DTPA-H11 scFv against A-375 cells in vitro ranged from 23% to 36%. 111In-DTPA-H11 scFv was rapidly eliminated from the blood and most normal tissues (except the kidneys) reaching maximum tumour/blood ratios of 12:1 at 48 h post-injection. Tumours were imaged as early as 40 min after injection. The kidneys accumulated the highest concentration of radioactivity (up to 185% injected dose/g). Tumour uptake was 1-3% injected dose/g. The whole-body radiation absorbed dose predicted for administration of 185 MBq of 111In-DTPA-H11 scFv to humans was 37 mSv. The radiation absorbed dose estimates for the kidneys, spleen and intestines were 405 mSv, 698 mSv and 412 mSv, respectively. The results of this preclinical study and a concurrent phase I trial suggest a promising role for H11 scFv for tumour imaging.
Assuntos
Radioisótopos de Índio , Melanoma/diagnóstico por imagem , Radioimunodetecção/métodos , Compostos Radiofarmacêuticos , Animais , Anticorpos Monoclonais , Feminino , Humanos , Região Variável de Imunoglobulina , Radioisótopos de Índio/farmacocinética , Cinética , Camundongos , Camundongos Nus , Ácido Pentético , Compostos Radiofarmacêuticos/farmacocinética , Distribuição Tecidual , Transplante Heterólogo , Células Tumorais CultivadasRESUMO
A phase I trial was conducted to evaluate the safety, tumour and normal tissue localization, pharmacokinetics and radiation dosimetry of Tc-hR3, a humanized monoclonal antibody directed towards the epidermal growth factor receptor, in 12 patients with recurrent or metastatic epithelial malignancies. Patients were injected intravenously with 3.0 mg or 6.0 mg (1010 MBq) of Tc-hR3. Blood and plasma concentrations of radioactivity were measured and a complete 24 h urine collection was obtained. Whole-body images were acquired up to 24 h post-injection and normal organ uptake quantified. Radiation dosimetry was estimated using MIRDose. Safety was evaluated by clinical observation, biochemical/haematological testing and by measuring immune response to Tc-hR3. There were no adverse effects, no changes in biochemical/haematological indices and no immune response to Tc-hR3. Tc-hR3 was rapidly cleared from the blood with a distribution half-life of 10.8+/-3.8 min. The volume of distribution, and clearance, were 180+/-37 ml.kg and 14+/-3 ml.kg.min, respectively. The elimination phase could not be discerned due to increasing blood radioactivity at later times. About 19-24% was excreted in the urine. Normal tissue uptake was mainly in the liver (44-50%), spleen (3-4%) and kidneys (3%). Imaging was positive in one patient with squamous cell carcinoma of the mouth and an involved cervical lymph node. The whole-body radiation dose from Tc-hR3 was 1.34+/-0.02x10 mSv.Bq. We conclude that Tc-hR3 exhibited an excellent safety profile. Future studies to determine the sensitivity and specificity of imaging with Tc-hR3 in a larger group of patients with pre-selection for epidermal growth factor receptor positivity are planned.